Cargando…
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
Somatic mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur frequently in acute myeloid leukemia (AML) and other cancers. These genes encode neomorphic proteins that produce the presumed oncometabolite 2-hydroxyglutarate (2-HG). Despite the prospect of treating AML and other ca...
Autores principales: | Chen, Chong, Liu, Yu, Lu, Chao, Cross, Justin R., Morris, John P., Shroff, Aditya S., Ward, Patrick S., Bradner, James E., Thompson, Craig, Lowe, Scott W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792474/ https://www.ncbi.nlm.nih.gov/pubmed/24065765 http://dx.doi.org/10.1101/gad.226613.113 |
Ejemplares similares
-
Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013) -
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020) -
Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021) -
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021) -
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)